TP53 and cancer: However, since development of the first-in-class MDM2 inhibitor nutlin-3a19, it has become evident that although these compounds effectively activate p53 and its downstream transcriptional program, including induction of numerous pro-apoptotic genes, most cancer cell types undergo a reversible cell cycle arrest response of little therapeutic value20.